<SEC-DOCUMENT>0001104659-21-084410.txt : 20210623
<SEC-HEADER>0001104659-21-084410.hdr.sgml : 20210623
<ACCEPTANCE-DATETIME>20210623074727
ACCESSION NUMBER:		0001104659-21-084410
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210623
FILED AS OF DATE:		20210623
DATE AS OF CHANGE:		20210623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		211037208

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2120489d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<BR>
</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Form 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Form 40-F</FONT>&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule&nbsp;101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule&nbsp;101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On June 23, 2021, CureVac N.V. (the &ldquo;Company&rdquo;)
issued a press release announcing that Dr. Ingmar Hoerr withdrew his candidacy for nomination to the Company's Supervisory Board and Dr. Timothy M. Wright will resign from
his role on the Company's Supervisory Board on June 24, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Form 6-K (including Exhibit
99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &ldquo;Exchange
Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: top; width: 28%"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 20%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 0.9in; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-top: 3pt; vertical-align: top; text-align: center"><A HREF="tm2120489d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-top: 3pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; vertical-align: top"><A HREF="tm2120489d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated June 23, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2120489d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Provides Supervisory Board Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>T&Uuml;BINGEN,
Germany / BOSTON, USA &#8211; June 23, 2021</B></FONT> &#8211; CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid (&#8220;mRNA&#8221;), today announced
that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination
to the Supervisory Board. Dr. Hoerr, who had retired from his duties with the company for acute health reasons in March 2020, has stated
continuing health problems, which do not allow him to resume his duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;I would like to express my deepest gratitude and respect to
Ingmar for his vision to advance new vaccine and therapeutic opportunities utilizing mRNA technology, and his tireless dedication in
building CureVac around this vision,&#8221; said Jean St&eacute;phenne, Chairman of the Supervisory Board of CureVac. &#8220;Ingmar&#8217;s
pioneering work in making mRNA accessible has helped to form the basis of a key technology that is now addressing today&#8217;s COVID-19
pandemic as well as future medical challenges in vaccines and therapeutics.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further announced that Dr. Timothy M. Wright is resigning from his role as Independent Director from CureVac&#8217;s Supervisory
Board to focus on his own professional endeavors. His resignation will become effective on June 24, 2021. Dr. Wright joined the CureVac
Supervisory Board in </FONT>June 2018 and served as member of the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;On behalf of our Board of Directors, I wish to thank Timothy
for investing his valuable time, talent, passion and wisdom to grow the Company. Timothy&#8217;s experience in drug development has helped
shape the Company and prepare it for a successful future,&#8221; added Jean St&eacute;phenne, Chairman of the Supervisory Board of CureVac.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CureVac is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile
biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA
as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its
proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered
in T&uuml;bingen, Germany, and employs more than 700 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information
can be found at </FONT><U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Sarah Fakih, Vice President Corporate Communications and Investor
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anna Kamilli, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +49 7071 9883-1684</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>anna.kamilli@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bettina J&ouml;dicke-Braas, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: 49 7071 9883-1087</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>bettina.joedicke-braas@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains statements that constitute &#8220;forward looking statements&#8221; as that term is defined in the United States
Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives,
assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc. and
CureVac Swiss AG (the &#8220;company&#8221;) regarding future events or future results, in contrast with statements that reflect historical
facts. Examples include discussion of the </FONT>potential efficacy of the company&#8217;s vaccine and treatment candidates and the company&#8217;s
strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements
by terminology such as &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221;
&#8220;seek,&#8221; &#8220;project,&#8221; or &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221;
&#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;should,&#8221; the negative of these terms or similar expressions. Forward-looking
statements are based on management&#8217;s current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company&#8217;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability
to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance
on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes
in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in
the company&#8217;s industry, the effects of the COVID-19 pandemic on the company&#8217;s business and results of operations, ability
to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and
fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements
to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&#8217;s
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or
developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&#8217;s reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC
website at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ *\# 2(  A$! Q$!_\0
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M;A[,,/C^'.)L/'FGD>=T(T)XE<KDJF3YG3G/)^(*#2YISR/'8^KA8.,\PPN
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M8U,DQ7$$\E]CB:]:5&K6KX.LL(L7ST:49T*$X?GM\41\3+7_ (*0>)I/A!X
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M&"BD9!P5!&0V\'&.H?Y@>S?,.>:F48R:<DI-:)O6VM^ZZZBY8_RQ_P# 8_\
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M0/C5X@^#6E^'/@UI&M:I\5DUCP=I%UH6B>&O#GB>*Z\'MK*Z5JUE-+J'W_\
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@8JS*&QD*S(C$ X)121E1A=JCHH'7L._7\\#/KB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
